Skip to main content

Table 8 Protective efficacy based on mITT by pooled group

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Studies pooled

Treatment

N

# of failures

Person-years

Incidence densitya

PE

95 % CI lower limit

95 % CI upper limit

030 and 045

Placebo

187

116

22.91

506.3

   

Tafenoquine 200-mg weekly

190

14

42.23

33.2

93.5

88.6

96.2

Mefloquine 250-mg weekly

142

8

28.67

27.9

94.5

88.7

97.3

030, 043 and 045

Placebo

247

170

30.59

555.7

   

Tafenoquine 200-mg weekly

245

21

54.44

38.6

93.1

89.1

95.6

  1. CI confidence interval, mITT modified intent-to-treat, N number of subjects, PE protective efficacy
  2. aIncidence density rate is expressed in terms of number of prophylactic failures per 100 person-years